MedTrace Logo

Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)

NCT00290069 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2007-05-15

No results posted yet for this study

Summary

The main aim of this study is to compare the renal function (serum creatinine at 6 months) in the later introduction of tacrolimus or rapamycin based in immunosuppressor regimes with daclizumab, mycophenolate mofetil, and steroids in patients older than 50 years of age who are the recipients of a graft from donors aged 55 years and older.

Conditions

Interventions

DRUG

Tacrolimus

DRUG

Rapamycin

Sponsors & Collaborators

  • Sociedad Andaluza de Trasplantes de Organos y Tejidos

    lead OTHER

Principal Investigators

  • Miguel A Gonzalez Molina, MD · Sociedad Andaluza de Trasplantes de Organos y Tejidos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290069 on ClinicalTrials.gov